These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 494575)

  • 21. Preparation of antihemophilic factor from indated plasma.
    Wickerhauser M
    Transfusion; 1976; 16(4):345-50. PubMed ID: 951729
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distribution of a bovine spongiform encephalopathy-derived agent over ion-exchange chromatography used in the preparation of concentrates of fibrinogen and factor VIII.
    Foster PR; Griffin BD; Bienek C; McIntosh RV; MacGregor IR; Somerville RA; Steele PJ; Reichl HE
    Vox Sang; 2004 Feb; 86(2):92-9. PubMed ID: 15023177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factor VIII collection by pheresis.
    McLeod BC; Sassetti RJ; Cole ER; Pierce MI
    Lancet; 1980 Sep; 2(8196):671-3. PubMed ID: 6106786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Factor VIII:C activity during heat inactivation of viruses in cryoprecipitates].
    Grgicević D; Flego I; Marchiotti I; Lupret L; Rajninger-Miholić M
    Lijec Vjesn; 1990; 112(7-8):212-5. PubMed ID: 2127297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An improved method for the preparation of intermediate-purity antihemophilic factor concentrate for therapeutic usage.
    Liu DT; Irwin JF; LeFave RO; Grzenczyk B; Pai RC
    Vox Sang; 1980; 38(4):216-21. PubMed ID: 6774479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Products for the treatment of hemophilia A and B prepared by ion exchange chromatography.
    Sultan Y; Boyeldieu D; Stieltjes N
    Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S59-60. PubMed ID: 8177717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of qucik and slow thaw methods of producing cryoprecipitate antihaemophilic factor from fresh and 24-hour-old blood.
    Bloom AL; Giddings JC; Bevan B; Letton M; Drummond RJ
    J Clin Pathol; 1969 Jul; 22(4):447-52. PubMed ID: 5798632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isolation and characterization of human factor VIII: molecular forms in commercial factor VIII concentrate, cryoprecipitate, and plasma.
    Andersson LO; Forsman N; Huang K; Larsen K; Lundin A; Pavlu B; Sandberg H; Sewerin K; Smart J
    Proc Natl Acad Sci U S A; 1986 May; 83(9):2979-83. PubMed ID: 3085106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of large-scale fractionation methods. VI. An improved method for preparation of antihemophilic factor.
    Wickerhauser M; Mercer JE; Eckenrode JW
    Vox Sang; 1978; 35(1-2):18-31. PubMed ID: 664566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Variations in cryoprecipitate production.
    Rock G; Tittley P
    Transfusion; 1977; 17(1):50-3. PubMed ID: 841673
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Large-scale preparation of a highly purified solvent-detergent treated factor VIII concentrate.
    Myers R; Wickerhauser M; Charamella L; Simon L; Nummy W; Brodniewicz-Proba T
    Vox Sang; 1991; 60(3):141-7. PubMed ID: 1907414
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Purification of the factor VIII complex.
    Thorell L; Blombäck B
    Thromb Res; 1984 Aug; 35(4):431-50. PubMed ID: 6435279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma exchange donation of cryoprecipitate after DDAVP stimulation: an alternative source of factor VIII.
    McLeod BC; Scott JP
    Prog Clin Biol Res; 1990; 324():189-98. PubMed ID: 2106687
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preparation of high-purity factor VIII by controlled pore glass chromatography.
    Margolis J; Rhoades PH
    Lancet; 1981 Aug; 2(8244):446-9. PubMed ID: 6115204
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of delayed blood processing on the yield of factor VIII in cryoprecipitate and factor VIII concentrate.
    Hughes C; Thomas KB; Schiff P; Herrington RW; Polacsek EE; McGrath KM
    Transfusion; 1988; 28(6):566-70. PubMed ID: 3143170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of type III von Willebrand's disease with solvent/detergent-treated factor VIII concentrates.
    Gazengel C; Fischer AM; Schlegel N; Rothschild C; Torchet MF; Dautzenberg MD; Aujard Y
    Nouv Rev Fr Hematol (1978); 1988; 30(4):225-7. PubMed ID: 3143100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chromatographic preparation of a therapeutic highly purified von Willebrand factor concentrate from human cryoprecipitate.
    Burnouf-Radosevich M; Burnouf T
    Vox Sang; 1992; 62(1):1-11. PubMed ID: 1580062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of heparin and calcium chloride on assay, stability, and recovery of factor VIII.
    Morgenthaler JJ; Zuber T; Friedli H
    Vox Sang; 1985; 48(1):8-17. PubMed ID: 3918394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of 'single donor' factor VIII from plasma exchange donation.
    McLeod BC; Scott JP
    JAMA; 1984 Nov; 252(19):2726-9. PubMed ID: 6436520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The influence of donor characteristics and preparation methods on the potency of human cryoprecipitate.
    Burka ER; Puffer T; Martinez J
    Transfusion; 1975; 15(4):323-8. PubMed ID: 1166505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.